AcelRx Pharmaceuticals (NASDAQ:ACRX) Stock Rating Reaffirmed by Credit Suisse Group

Credit Suisse Group reissued their outperform rating on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) in a research report sent to investors on Wednesday, Briefing.com Automated Import reports.

ACRX has been the subject of a number of other research reports. Zacks Investment Research raised DLH from a sell rating to a hold rating in a research note on Tuesday. B. Riley reissued a buy rating on shares of Champion Iron in a research note on Wednesday, April 24th. LADENBURG THALM/SH SH reissued a buy rating on shares of Paratek Pharmaceuticals in a research note on Thursday, May 9th. ValuEngine raised VESTAS WIND SYS/ADR from a hold rating to a buy rating in a research note on Thursday, May 9th. Finally, BidaskClub lowered Zai Lab from a hold rating to a sell rating in a research note on Wednesday, May 1st. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of Buy and an average price target of $7.47.

NASDAQ ACRX opened at $2.77 on Wednesday. AcelRx Pharmaceuticals has a 1-year low of $1.99 and a 1-year high of $5.05. The company has a debt-to-equity ratio of 0.79, a current ratio of 5.03 and a quick ratio of 4.91. The firm has a 50-day moving average of $2.46.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The company had revenue of $0.27 million during the quarter, compared to the consensus estimate of $0.85 million. Equities research analysts forecast that AcelRx Pharmaceuticals will post -0.84 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Resources Investment Advisors Inc. bought a new position in AcelRx Pharmaceuticals during the 1st quarter valued at approximately $34,000. WINTON GROUP Ltd bought a new position in AcelRx Pharmaceuticals during the 2nd quarter valued at approximately $40,000. Raymond James & Associates raised its position in AcelRx Pharmaceuticals by 96.7% during the 4th quarter. Raymond James & Associates now owns 29,500 shares of the specialty pharmaceutical company’s stock valued at $68,000 after purchasing an additional 14,500 shares during the last quarter. First National Bank of Mount Dora Trust Investment Services bought a new position in AcelRx Pharmaceuticals during the 1st quarter valued at approximately $70,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in AcelRx Pharmaceuticals during the 1st quarter valued at approximately $79,000. 15.53% of the stock is owned by institutional investors and hedge funds.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

See Also: Why are trading ranges significant?

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.